CharlestonPharma is a biotechnology company specializing in the development of fully human monoclonal antibodies that specifically target nucleolin in the plasma membrane and cytoplasm of tumor cells. These antibodies have shown promising results in in vitro, ex vivo, and in vivo studies, demonstrating high selectivity for tumor cells over normal tissues. The company operates in the oncology market, serving healthcare providers and researchers focused on cancer treatment. CharlestonPharma's business model involves research and development of these antibodies, followed by clinical trials and eventual commercialization. Revenue is generated through partnerships, licensing agreements, and sales of their proprietary antibodies. The company is led by experienced executives with a strong background in biotechnology and oncology drug development.

Keywords: monoclonal antibodies, nucleolin, cancer treatment, biotechnology, oncology, tumor cells, clinical trials, healthcare, drug development, selective targeting.